Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ANGLE plc ( (GB:AGL) ) just unveiled an update.
ANGLE plc presented new data at the EACR 2025 Congress, highlighting its DNA dual analysis approach using the Parsortix system in collaboration with Illumina. The study demonstrated the system’s ability to reveal tumour heterogeneity in lung cancer patients by analyzing both CTC-DNA and ctDNA, offering valuable insights for biopharma partners in identifying drug targets and improving trial outcomes.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
More about ANGLE plc
ANGLE plc is a world-leading liquid biopsy company specializing in circulating tumour cell (CTC) solutions for research, drug development, and clinical oncology. The company offers clinical services and diagnostic products, including the Parsortix system, which enables comprehensive downstream analysis of blood samples for genomic and transcriptomic insights.
Average Trading Volume: 1,351,668
Technical Sentiment Signal: Sell
Current Market Cap: £23.38M
For detailed information about AGL stock, go to TipRanks’ Stock Analysis page.